Mesenchymal stem cells (MSCs) have shown potential for treating COPD. COPD is a severe lung injury caused by inflammation, leading to damage to the alveoli (tiny air sacs in the lungs) and impaired oxygen exchange, resulting in severe breathing problems. MSCs can suppress inflammation and promote tissue repair, making them a potentially effective treatment for COPD.
When injected intravenously into the bloodstream, MSCs reach the lungs and begin to act on various cell types involved in the inflammation response. MSCs secrete anti-inflammatory cytokines (proteins that control the immune response) and growth factors, which reduce inflammation, promote tissue regeneration, and repair the damaged alveoli. MSCs also have a paracrine effect, which means they can signal to neighbouring cells to promote tissue regeneration and keep the lung tissue healthy.
MSCs have been observed to reduce the inflammation and increase the survival rate of people with COPD. MSCs have also been used in clinical trials with COPD patients, where they have shown potential in improving oxygen saturation and reducing the need for mechanical ventilation.
In summary, MSCs can mitigate the inflammation response caused by COPD and promote lung tissue repair, making them an exceptional therapeutic option for COPD patients.
